Functional Dyspepsia, Peptic Ulcer
Conditions
Keywords
eradication, helicobacter pylori, bismuth
Brief summary
To examine and compare the efficacy of 2 week Levofloxacin-containing therapies with and without Bismuth for H.pylori treatment.
Detailed description
The success rate of the standard triple therapy for H. pylori infection is decreasing recently.Fluoroquinolone has been proposed to replace clarithromycin as an alternative in the treatment. However prevalence of H.pylori resistance to Levofloxacin has increased rapidly in our area. The purpose of this study is to observe the efficacy of 14 day Levofloxacin triple therapy-based, bismuth-containing quadruple therapy for H.pylori treatment.
Interventions
DRUGBismuth
Bismuth 220mg b.i.d for 2 weeks
DRUGLansoprazole
Lansoprazole 30 mg b.i.d.for 2 weeks
DRUGLevofloxacin
Levofloxacin 0.5 q.d. for 2 weeks
DRUGAmoxicillin
Amoxicillin 1 g b.i.d. for 2 weeks
Sponsors
Shanghai Jiao Tong University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* patients who presented with upper gastrointestinal symptoms and endoscopically proven H.pylori-positive functional dyspepsia and scarred peptic ulcer
Exclusion criteria
* patients with peptic ulcer, previous H.pylori eradication therapy, previous gastric surgery, pregnancy, lactation, major systemic diseases, receipt of anti-secretory therapy, antibiotics or bismuth in the preceding 4 weeks, or allergy to any one of the medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eradication rate of Helicobacter pylori | 2 months |
Countries
China
Outcome results
None listed